Physician profile
Jeffrey Harbold
NPI 1700260197
$5,845.94
in general payments reported to CMS, 2019-2025
21 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2021: $489 · 2022: $158 · 2023: $1,246 · 2024: $1,797 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,835.33 |
| Education | $218.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,339.59 | 2023-2025 | |
| Genzyme Corporation | $1,104.21 | 2021-2025 | |
| Janssen Biotech, INC. | $740.49 | 2023-2025 | Tremfya, Stelara, Remicade |
| Galderma Laboratories, L.P. | $520.75 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $405.87 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $312.06 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $211.93 | 2023-2025 | |
| Pfizer INC. | $211.42 | 2024-2025 | |
| Ucb, INC. | $172.04 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $151.18 | 2023-2024 | Ilumya |
| Lilly USA, LLC | $141.17 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Scientific Affairs, LLC | $96.71 | 2021 | |
| Arcutis Biotherapeutics, INC. | $91.43 | 2024-2025 | Zoryve |
| Incyte Corporation | $89.39 | 2022-2024 | Opzelura |
| Amgen INC. | $61.12 | 2023-2025 | Otezla, Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $55.02 | 2024 | Adbry |
| Organon LLC | $50.71 | 2025 | Vtama |
| Dermavant Sciences, INC. | $36.57 | 2024 | Vtama |
| Celgene Corporation | $20.34 | 2019 | |
| Botanix Sb INC | $18.18 | 2025 | Sofdra |
| Journey Medical Corporation | $15.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Harbold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.